Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper

Br J Haematol. 2024 Apr;204(4):1193-1206. doi: 10.1111/bjh.19333. Epub 2024 Feb 23.

Abstract

Multiple myeloma is a bone marrow-based plasma cell tumour that develops from asymptomatic pre-cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high-risk disease may be available. Restaging is required if evidence for progression.

Keywords: MGUS; multiple myeloma; myeloma therapy; myeloma.

Publication types

  • News

MeSH terms

  • Disease Progression
  • Hematology*
  • Humans
  • Monoclonal Gammopathy of Undetermined Significance* / diagnosis
  • Monoclonal Gammopathy of Undetermined Significance* / pathology
  • Monoclonal Gammopathy of Undetermined Significance* / therapy
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / pathology
  • Multiple Myeloma* / therapy
  • Plasma Cells / pathology
  • Smoldering Multiple Myeloma* / diagnosis
  • Smoldering Multiple Myeloma* / pathology
  • Smoldering Multiple Myeloma* / therapy